The strategic use of novel smallpox vaccines in the post-eradication world

References

• Moss B. Poxviruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott, Williams and Wilkins, Philadelphia, PA, USA, 2905–2946 (2007).
   Google Scholar
• Damon I. Poxviruses In: Fields Virology. Knipe DM, Howley PM (Eds). Lippencott, Williams and Wilkins, Philadelphia, PA, USA, 2947–2976 (2007).
   Google Scholar
• Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi ID. Smallpox and Its Eradication. World Health Organization, Geneva, Switzerland (1988).
   Google Scholar
• Hopkins DR. The Greatest Killer: Smallpox in History, With a New Introduction. University of Chicago Press, Chicago, IL, USA (2002).
   Google Scholar
• Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann. Intern. Med.127(8 Pt 1), 635–642 (1997).
   PubMed Web of Science ®Google Scholar
• Eyler JM. Smallpox in history: the birth, death, and impact of a dread disease. J. Lab. Clin. Med.142(4), 216–220 (2003).
   PubMedGoogle Scholar
• Klebs AC, Lausanne MD. The historic evolution of variolation. The Johns Hopkins Hospital Bulletin24(265), 1–66 (1913).
   Google Scholar
• Dinc G, Ulman YI. The introduction of variolation ‘A La Turca’ to the West by Lady Mary Montagu and Turkey’s contribution to this. Vaccine25(21), 4261–4265 (2007).
   Google Scholar
• Jenner E. Inquiry into the Causes and Effects of the Variolae Vaccine. Murray and Highley, London, UK (1798).
   Google Scholar
• Dudgeon JA. Development of smallpox vaccine in England in the eighteenth and nineteenth Centuries. BMJ1(5342), 1367–1372 (1963).
   Google Scholar
• Nalca A, Hatkin JM, Garza NL et al. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res.79(2), 121–127 (2008).
   Google Scholar
• Appleyard G, Hapel AJ, Boulter EA. An antigenic difference between intracellular and extracellular rabbitpox virus. J. Gen. Virol.13(1), 9–17 (1971).
   PubMedGoogle Scholar
• Boulter EA. Protection against poxviruses. Proc. R. Soc. Med.62(3), 295–297 (1969).
   PubMedGoogle Scholar
• Turner GS, Squires EJ. Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. J. Gen Virol.13(1), 19–25 (1971).
   PubMedGoogle Scholar
• Turner GS, Squires EJ, Murray HG. Inactivated smallpox vaccine. A comparison of inactivation methods. J. Hyg. (Lond.)68(2), 197–210 (1970).
   Google Scholar
• Rivers TM, Ward SM. Jennerian prophylaxis by means of intradermal injections of culture vaccine virus. J. Exp. Med.62(4), 549–560 (1935).
   PubMedGoogle Scholar
• Rivers TM, Ward SM, Baird RD. Amount and duration of immunity induced by intradermal inoculation of cultured vaccine virus. J. Exp. Med.69(6), 857–866 (1939).
   PubMedGoogle Scholar
• Kempe CH, Fulginiti V, Minamitani M, Shinefield H. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78). Pediatrics42(6), 980–985 (1968).
   PubMedGoogle Scholar
• Wesley RB, Speers WC, Neff JM, Ruben FL, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination. Pediatric Res.9(8), 624–628 (1975).
   PubMed Web of Science ®Google Scholar
• Speers WC, Wesley RB, Neff JM, Goldstein J, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. II. Clinical and serologic observations of response to revaccination with calf lymph vaccine. Pediatric Res.9(8), 628–632 (1975).
   PubMed Web of Science ®Google Scholar
• Hochstein-Mintzel V, Hanichen T, Huber HC, Stickl H. An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola. Zentralbl. Bakteriol. Orig. A230(3), 283–297 (1975).
   PubMedGoogle Scholar
• McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis.38(12), 1749–1753 (2004).
   PubMed Web of Science ®Google Scholar
• Slifka MK. The future of smallpox vaccination: is MVA the key? Med. Immunol. (Lond.)4(1), 2 (2005).
   PubMedGoogle Scholar
• Hashizume S, Yoshizawa H, Morita M, Suzuki Kp-IGVQe, Vaccinia viruses as vectors for vaccine antigens. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Vaccinia Viruses as Vectors for Vaccine Antigens. Quainnan GV (Ed.). Elsevier Science Publishing Co, Amsterdam, The Netherlands, 421–428 (1985).
   Google Scholar
• Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine24(47–48), 7009–7022 (2006).
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, McIntyre L (Eds). Public Health Foundation, Washington, DC, USA (2006).
   Google Scholar
• Shooter RA. Report on the Investigation into the Cause of the 1978 Birmingham Smallpox Occurrence. Her Majesty’s Stationery Office, London, UK (1980).
   Google Scholar
• World Health Organization. No smallpox. Wkly Epidemiol. Rec.54, 329–336 (1979).
   Google Scholar
• Kortepeter MG, Parker GW. Potential biological weapons threats. Emerg. Infect. Dis.5(4), 523–527 (1999).
   PubMed Web of Science ®Google Scholar
• Fenn EA. Biological warfare in eighteenth-Century North America: beyond Jeffery Amherst. J. Am. Hist.86(4), 1552–1580 (2000).
   PubMed Web of Science ®Google Scholar
• Alibek K. Smallpox: a disease and a weapon. Int. J. Infect. Dis.8(Suppl. 2), S3–S8 (2004).
   Google Scholar
• Frischknecht F. The history of biological warfare. Human experimentation, modern nightmares and lone madmen in the twentieth Century. EMBO Rep.4(Spec No.), S47–S52 (2003).
   PubMedGoogle Scholar
• Shoham D, Wolfson Z. The Russian biological weapons program: vanished or disappeared?. Crit Rev. Microbiol.30(4), 241–261 (2004).
   PubMed Web of Science ®Google Scholar
• Graham B, Talent J. Bioterrorism: redefining prevention. Biosecur. Bioterror.7(2), 125–126 (2009).
   PubMed Web of Science ®Google Scholar
• Domi A, Moss B. Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc. Natl Acad. Sci. USA99(19), 12415–12420 (2002).
   PubMed Web of Science ®Google Scholar
• Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science (New York)297(5583), 1016–1018 (2002).
   Google Scholar
• Wimmer E, Mueller S, Tumpey TM, Taubenberger JK. Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat. Biotechnol.27(12), 1163–1172 (2009).
   Google Scholar
• Smith GL, McFadden G. Smallpox: anything to declare? Nat. Rev. Immunol.2(7), 521–527 (2002).
   PubMed Web of Science ®Google Scholar
• Center for Diseaes Control and Prevention. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.50(RR-10), 1–25 (2001).
   PubMedGoogle Scholar
• Center for Diseaes Control and Prevention. Recommendations for using smallpox vaccine in a prevent vaccinatino program: supplemental recommendation sof the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Morb. Mortal. Wkly Rep.52(RR-7), 1–16 (2003).
   PubMedGoogle Scholar
• Kwon N, Raven MC, Chiang WK et al. Emergency physicians’ perspectives on smallpox vaccination. Acad. Emerg. Med.10(6), 599–605 (2003).
   PubMed Web of Science ®Google Scholar
• Schraeder TL, Campion EW. Smallpox vaccination – the call to arms. N. Engl. J. Med.348(5), 381–382 (2003).
   Google Scholar
• Yih WK, Lieu TA, Rego VH et al. Attitudes of healthcare workers in U.S. hospitals regarding smallpox vaccination. BMC Public Health3, 20 (2003).
   Google Scholar
• Strikas RA, Neff LJ, Rotz L et al. US civilian smallpox preparedness and response program, 2003. Clin. Infect. Dis.46(Suppl. 3), S157–S167 (2008).
   PubMed Web of Science ®Google Scholar
• Casey CG, Iskander JK, Roper MH et al. Adverse events associated with smallpox vaccination in the United States, January–October 2003. JAMA294(21), 2734–2743 (2005).
   PubMed Web of Science ®Google Scholar
• Clark PT, Levin S. The Smallpox vaccine injury compensation program. Clin. Infect. Dis.46(Suppl. 3), S179–S181 (2008).
   Google Scholar
• Kaplan EH, Craft DL, Wein LM. Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl Acad. Sci. USA99(16), 10935–10940 (2002).
   PubMed Web of Science ®Google Scholar
• Meltzer MI, Damon I, LeDuc JW, Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis.7(6), 959–969 (2001).
   PubMed Web of Science ®Google Scholar
• O’Toole T, Mair M, Inglesby TV. Shining light on “Dark Winter”. Clin. Infect. Dis.34(7), 972–983 (2002).
   PubMed Web of Science ®Google Scholar
• Bicknell WJ. The case for voluntary smallpox vaccination. N. Engl. J. Med.346(17), 1323–1325 (2002).
   PubMed Web of Science ®Google Scholar
• Handley L, Buller RM, Frey SE, Bellone C, Parker S. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev. Vaccines8(7), 841–850 (2009).
   PubMed Web of Science ®Google Scholar
• Mortimer PP. Can postexposure vaccination against smallpox succeed? Clin. Infect. Dis.36(5), 622–629 (2003).
   PubMed Web of Science ®Google Scholar
• Bicknell WJ, James K. Smallpox vaccination after a bioterrorism-based exposure. Clin. Infect. Dis.37(3), 467 (2003).
   PubMed Web of Science ®Google Scholar
• Bicknell W, James K. The new cell culture smallpox vaccine should be offered to the general population. Rev. Med. Virol.13(1), 5–15 (2003).
   Google Scholar
• Fauci AS. Smallpox vaccination policy – the need for dialogue. N. Engl. J. Med.346(17), 1319–1320 (2002).
   Google Scholar
• Hilleman MR. Overview: cause and prevention in biowarfare and bioterrorism. Vaccine20(25–26), 3055–3067 (2002).
   PubMed Web of Science ®Google Scholar
• Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des. Dev. Ther.4, 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Weltzin R, Liu J, Pugachev KV et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med.9(9), 1125–1130 (2003).
   PubMed Web of Science ®Google Scholar
• ACAM2000®, package insert. Acambis, Cambridge, UK.
   Google Scholar
• Lane JM, Goldstein J. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis.14(3), 189–195 (2003).
   Google Scholar
• Copeman PW, Wallace HJ. Eczema vaccinatum. BMJ2(5414), 906–908 (1964).
   PubMedGoogle Scholar
• Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N. Engl. J. Med.281(22), 1201–1208 (1969).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Household transmission of vaccinia virus from contact with a military smallpox vaccinee – Illinois and Indiana, 2007. MMWR Morb. Mortal. Wkly Rep.56(19), 478–481 (2007).
   PubMedGoogle Scholar
• Monath TP, Frey SE. Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine27(10), 1645–1650 (2009).
   Google Scholar
• Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev. Vaccines8(1), 13–24 (2009).
   PubMed Web of Science ®Google Scholar
• Earl PL, Americo JL, Wyatt LS et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature428(6979), 182–185 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine26(14), 1794–1804 (2008).
   PubMed Web of Science ®Google Scholar
• Earl PL, Americo JL, Wyatt LS et al. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology366(1), 84–97 (2007).
   Google Scholar
• Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology244(2), 365–396 (1998).
   PubMed Web of Science ®Google Scholar
• Meisinger-Henschel C, Schmidt M, Lukassen S et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol.88(Pt 12), 3249–3259 (2007).
   PubMedGoogle Scholar
• Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen Virol.72(Pt 5), 1031–1038 (1991).
   PubMed Web of Science ®Google Scholar
• Meisinger-Henschel C, Spath M, Lukassen S et al. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice. J. Virol.84(19), 9907–9919 (2010).
   Google Scholar
• Zwilling J, Sliva K, Schwantes A, Schnierle B, Sutter G. Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells. Virology404(2), 231–239 (2010).
   Google Scholar
• US FDA Fast Track status for IMVAMUNE. Hum. Vaccin.6(5), 368–372 (2010).
   Google Scholar
• Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Curr. Opin. Immunol.21(3), 314–320 (2009).
   PubMed Web of Science ®Google Scholar
• Good RA, Zak SJ, Condie RM, Bridges RA. Clinical investigation of patients with agammaglobulinemia and hypogammaglobulinemia. Pediatr. Clin. North Am.7, 397–433 (1960).
   Google Scholar
• Fulginiti V, Kempe CH, Hathaway WE et al. Progressive vaccinia in immunologically deficient individuals. Birth Defects4, 129–145 (1968).
   Google Scholar
• Edghill-Smith Y, Golding H, Manischewitz J et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med.11(7), 740–747 (2005).
   PubMed Web of Science ®Google Scholar
• Panchanathan V, Chaudhri G, Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc. Natl Acad. Sci. USA102(36), 12921–12926 (2005).
   Google Scholar
• Panchanathan V, Chaudhri G, Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol.80(13), 6333–6338 (2006).
   PubMed Web of Science ®Google Scholar
• Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol.79(21), 13454–13462 (2005).
   PubMed Web of Science ®Google Scholar
• McCausland MM, Benhnia MR, Crickard L et al. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antiviral Ther.15(4), 661–675 (2010).
   PubMed Web of Science ®Google Scholar
• Davies DH, Liang X, Hernandez JE et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl Acad. Sci. USA102(3), 547–552 (2005).
   PubMed Web of Science ®Google Scholar
• Sette A, Grey H, Oseroff C et al. Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine27(Suppl. 6), G21–G26 (2009).
   PubMedGoogle Scholar
• Xu RH, Cohen M, Tang Y et al. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med.205(4), 981–992 (2008).
   Google Scholar
• Golden JW, Hooper JW. Evaluating the orthopoxvirus type I interferon binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model. Clin. Vaccine Immunol.17(11), 1656–1665 (2010).
   Google Scholar
• Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol.78(13), 7052–7060 (2004).
   PubMed Web of Science ®Google Scholar
• Isaacs SN. Improved smallpox vaccines. In: New Generation Vaccines. Levine MM, Dougan G, Good MF et al. (Eds). Informa Helthcare, New York, NY, USA, 838–850 (2010).
   Google Scholar
• Berhanu A, Wilson RL, Kirkwood-Watts DL et al. Vaccination of BALB/c mice with Escherichia coli -expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J. Virol.82(7), 3517–3529 (2008).
   PubMed Web of Science ®Google Scholar
• Davies DH, McCausland MM, Valdez C et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol.79(18), 11724–11733 (2005).
   PubMed Web of Science ®Google Scholar
• Braxton CL, Puckett SH, Mizel SB, Lyles DS. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J. Virol.84(7), 3552–3561 (2010).
   Google Scholar
• Buchman GW, Cohen ME, Xiao Y et al. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine28(40), 6627–6636 (2010).
   PubMed Web of Science ®Google Scholar
• Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol.78(19), 10230–10237 (2004).
   PubMed Web of Science ®Google Scholar
• Fogg CN, Americo JL, Lustig S et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine25(15), 2787–2799 (2007).
   PubMedGoogle Scholar
• Heraud JM, Edghill-Smith Y, Ayala V et al. Subunit recombinant vaccine protects against monkeypox. J. Immunol.177(4), 2552–2564 (2006).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology266(2), 329–339 (2000).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology306(1), 181–195 (2003).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Ferro AM, Golden JW et al. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine28(2), 494–511 (2009).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine25(10), 1814–1823 (2007).
   PubMed Web of Science ®Google Scholar
• Kaufman DR, Goudsmit J, Holterman L et al. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J. Virol.82(14), 6829–6837 (2008).
   Google Scholar
• Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine22(25–26), 3358–3366 (2004).
   PubMed Web of Science ®Google Scholar
• Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology355(2), 164–174 (2006).
   PubMed Web of Science ®Google Scholar
• Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology371(1), 98–107 (2007).
   Google Scholar
• Xiao Y, Aldaz-Carroll L, Ortiz AM et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine25(7), 1214–1224 (2007).
   PubMed Web of Science ®Google Scholar
• Demkowicz WE, Maa JS, Esteban M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J. Virol.66(1), 386–398 (1992).
   PubMed Web of Science ®Google Scholar
• Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology254(1), 71–80 (1999).
   PubMed Web of Science ®Google Scholar
• Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology325(2), 425–431 (2004).
   PubMed Web of Science ®Google Scholar
• Golden JW, Hooper JW. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology377(1), 19–29 (2008).
   PubMed Web of Science ®Google Scholar
• Aldaz-Carroll L, Xiao Y, Whitbeck JC et al. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J. Virol.81(15), 8131–8139 (2007).
   PubMed Web of Science ®Google Scholar
• Biswas S, Kalanidhi AP, Ashok MS, Reddy GS, Srinivasan VA, Rangarajan PN. Evaluation of rabies virus neutralizing antibody titres induced by intramuscular inoculation of rabies DNA vaccine in mice and Bonnet monkeys (Macaca radiata). Indian J. Exp. Biol.39(6), 533–536 (2001).
   Google Scholar
• Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine27(5), 748–756 (2009).
   PubMed Web of Science ®Google Scholar
• Carnes AE, Williams JA. Plasmid DNA manufacturing technology. Recent Pat. Biotechnol.1(2), 151–166 (2007).
   PubMedGoogle Scholar
• Forde GM. Rapid-response vaccines – does DNA offer a solution? Nat. Biotechnol.23(9), 1059–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Boni J, Stalder J, Reigel F, Schupbach J. Detection of reverse transcriptase activity in live attenuated virus vaccines. Clin. Diagn. Virol.5(1), 43–53 (1996).
   Google Scholar
• Tsang SX, Switzer WM, Shanmugam V et al. Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps vaccines derived from chicken cells: investigation of transmission to vaccine recipients. J. Virol.73(7), 5843–5851 (1999).
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Jordan R, King DS et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine26(7), 933–946 (2008).
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol.21(3), 346–351 (2009).
   PubMed Web of Science ®Google Scholar
• Wang S, Pal R, Mascola JR et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology350(1), 34–47 (2006).
   PubMed Web of Science ®Google Scholar
• Hensley LE, Mulangu S, Asiedu C et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog.6(5), e1000904 (2010).
   PubMed Web of Science ®Google Scholar
• Wei CJ, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science329(5995), 1060–1064 (2010).
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine28(17), 2999–3007 (2010).
   PubMed Web of Science ®Google Scholar
• Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S. Heterologous HA DNA vaccine prime–inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine26(29–30), 3626–3633 (2008).
   PubMed Web of Science ®Google Scholar
• Richmond JF, Lu S, Santoro JC et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J. Virol.72(11), p9092–p9100 (1998).
   PubMed Web of Science ®Google Scholar
• Wang S, Arthos J, Lawrence JM et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J. Virol.79(12), 7933–7937 (2005).
   PubMed Web of Science ®Google Scholar
• Essbauer S, Pfeffer M, Meyer H. Zoonotic poxviruses. Vet. Microbiol.140(3–4), 229–236 (2010).
   PubMed Web of Science ®Google Scholar
• Rimoin AW, Mulembakani PM, Johnston SC et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl Acad. Sci. USA107(37), 16262–16267 (2010).
   PubMed Web of Science ®Google Scholar
• Cho CT, Wenner HA. Monkeypox virus. Bacteriol. Rev.37(1), 1–18 (1973).
   PubMedGoogle Scholar
• Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis.4(1), 15–25 (2004).
   PubMed Web of Science ®Google Scholar
• Reed KD, Melski JW, Graham MB et al. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med.350(4), 342–350 (2004).
   PubMed Web of Science ®Google Scholar
• Egberink HF, Willemse A, Horzinek MC. Isolation and identification of a poxvirus from a domestic cat and a human contact case. Zentralbl. Veterinarmed B33(3), 237–240 (1986).
   Google Scholar
• Willemse A, Egberink HF. Transmission of cowpox virus infection from domestic cat to man. Lancet1(8444), 1515 (1985).
   Google Scholar
• Kurth A, Wibbelt G, Gerber HP, Petschaelis A, Pauli G, Nitsche A. Rat-to-elephant-to-human transmission of cowpox virus. Emerg. Infect. Dis.14(4), 670–671 (2008).
   Google Scholar
• Kurth A, Straube M, Kuczka A, Dunsche AJ, Meyer H, Nitsche A. Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans. PLoS ONE4(9), e6883 (2009).
   Google Scholar
• Marennikova SS, Maltseva NN, Korneeva VI, Garanina VM. Pox infection in Carnivora of the family Felidae.Acta Virol.19(3), 260 (1975).
   Google Scholar
• Marennikova SS, Shelukhina EM, Fimina VA. Pox infection in white rats. Lab. Anim.12(1), 33–36 (1978).
   Google Scholar
• Glatz M, Richter S, Ginter-Hanselmayer G, Aberer W, Mullegger RR. Human cowpox in a veterinary student. Lancet Infect. Dis.10(4), 288 (2010).
   Google Scholar
• Bhanuprakash V, Venkatesan G, Balamurugan V et al. Zoonotic Infections of Buffalopox in India. Zoonoses and Public Health57(7–8), e149–e155 (2009).
   Google Scholar
• Trindade GS, Emerson GL, Carroll DS, Kroon EG, Damon IK. Brazilian vaccinia viruses and their origins. Emerg. Infect. Dis.13(7), 965–972 (2007).
   PubMed Web of Science ®Google Scholar
• Singh RK, Hosamani M, Balamurugan V, Bhanuprakash V, Rasool TJ, Yadav MP. Buffalopox: an emerging and re-emerging zoonosis. Anim. Health Res. Rev.8(1), 105–114 (2007).
   Google Scholar
• Abrahao JS, Silva-Fernandes AT, Lima LS et al. Vaccinia virus infection in monkeys, Brazilian Amazon. Emerg. Infect. Dis.16(6), 976–979 (2010).
   Google Scholar
• Medaglia ML, Pessoa LC, Sales ER, Freitas TR, Damaso CR. Spread of cantagalo virus to northern Brazil. Emerg. Infect. Dis.15(7), 1142–1143 (2009).
   Google Scholar
• Silva-Fernandes AT, Travassos CE, Ferreira JM et al. Natural human infections with Vaccinia virus during bovine vaccinia outbreaks. J. Clin. Virol.44(4), 308–313 (2009).
   Google Scholar
• Croft DR, Sotir MJ, Williams CJ et al. Occupational risks during a monkeypox outbreak, Wisconsin, 2003. Emerg. Infect. Dis.13(8), 1150–1157 (2007).
   PubMed Web of Science ®Google Scholar
• Kuntze A. Elephant pox and microsporum infection-two zoonoses of relevance to the zoo veterinarian. Presented at: European Association of Zoo- and Wildlife Veterinarians, Second scientific meeting. Chester, UK, 21–24 May 1998.
   Google Scholar
• Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol.79(Pt 2), 347–352 (1998).
   PubMed Web of Science ®Google Scholar
• Redding L, Weiner DB. DNA vaccines in veterinary use. Expert Rev. Vaccines8(9), 1251–1276 (2009).
   PubMed Web of Science ®Google Scholar
• Gronvall GK, Trent D, Borio L, Brey R, Nagao L. The FDA animal efficacy rule and biodefense. Nat. Biotechnol.25(10), 1084–1087 (2007).
   PubMed Web of Science ®Google Scholar
• Yang G, Pevear DC, Davies MH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol.79(20), 13139–13149 (2005).
   PubMed Web of Science ®Google Scholar
• Atlas R, Rubin C, Maloy S, Daszak P, Colwell R, Hyde B. One health-attaining optimal health for people, animals and the environment. Microbe5(9), 383–389 (2010).
   Google Scholar
• Orent W. Will Monkeypox be the Next Smallpox? In: Los Angeles Times. Russ Stanton (Ed.). Los Angeles, CA, USA (2010).
   Google Scholar
• Sassetti CM, Rubin EJ. The open book of infectious diseases. Nat. Med.13(3), 279–280 (2007).
   Google Scholar
• Garza NL, Hatkin JM, Livingston V et al. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine27(40), 5496–5504 (2009).
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Schmaljohn CS. DNA vaccines for biodefense. Expert Rev. Vaccines8(12), 1739–1754 (2009).
   PubMed Web of Science ®Google Scholar
• Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine26(27–28), 3507–3515 (2008).
   PubMed Web of Science ®Google Scholar
• Rudraraju R, Ramsay AJ. Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection. Vaccine28(31), 4997–5004 (2010).
   Google Scholar
• Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology345(1), 231–243 (2006).
   PubMed Web of Science ®Google Scholar
• Shinoda K, Wyatt LS, Moss B. The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein. Virology405(1), 41–49 (2010).
   Google Scholar
• Graham BS, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis.194(12), 1650–1660 (2006).
   PubMed Web of Science ®Google Scholar
• Geier MR, Geier DA, Zahalsky AC. A review of hepatitis B vaccination. Expert Opin. Drug Safety2(2), 113–122 (2003).
   PubMedGoogle Scholar
• Abraham P, Mistry FP, Bapat MR et al. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine17(9–10), 1125–1129 (1999).
   Google Scholar
• Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol.13(11), 1267–1277 (2006).
   PubMed Web of Science ®Google Scholar
• Martin JE, Pierson TC, Hubka S et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a Phase 1 clinical trial. J. Infect. Dis.196(12), 1732–1740 (2007).
   PubMed Web of Science ®Google Scholar
• Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled Phase 1b clinical trial. Vaccine27(18), 2506–2512 (2009).
   PubMed Web of Science ®Google Scholar